I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

EURETINA 2026

We will be contributing to topics related to
-
06:00 AM
Duration 60mins Vienna, Austria
Reduction in Subretinal Hyperreflective Material Volume With Faricimab▼ vs Aflibercept 2 mg in Treatment-Naïve nAMD: An Analysis of TENAYA/LUCERNE
Nirojini Sivachandran, Jesse Jung, Isabel Bachmeier, Lei Han, Andreas Maunz, Shriji Patel, Xiaoying Yang, Siqing Yu, Philippe Margaron, Srinivas Sadd
Duration 60mins Vienna, Austria
Impact of Baseline Subretinal Fluid on Treatment Outcomes in DME: Analysis of the Phase 3 YOSEMITE and RHINE Trials
Jorge Ruiz Medrano, Alabi R, Han L, Warter A, Amador M, Gibson K
Duration 60mins Vienna, Austria
One–Year Clinical and Anatomical Outcomes of Faricimab▼ Treatment in Eyes With DME From the Global, Prospective Observational VOYAGER Study
Veeral Sheth, Lövestam-Adrian M, Chaudhary V, Schmitz-Valckenberg S, Parravano M, Bailey C, Chaikitmongkol V, Chi G, Finger R, Ishida S, Uschner D, Koh A, Schweitzer J, Souied E, Guymer R
Duration 60mins Vienna, Austria
Anatomical Outcomes of Faricimab▼ in Patients With Neovascular Age-Related Macular Degeneration: 12-Month Real-World Imaging From the VOYAGER Study
Claire Bailey, Ishida S, Schmitz-Valckenberg S, Parravano M, Chaudhary V, Finger R, Albrecht T, Uschner D, Koh A, Lövestam-Adrian M, Luna Pinto J, Schweitzer J, Sheth V, Souied E, Guymer R
Duration 60mins Vienna, Austria
Anatomical Outcomes of Faricimab▼ in Patients With Diabetic Macular Edema: 12-Month Real-World Imaging From the VOYAGER Study
Adrian Koh, Finger R, Schmitz-Valckenberg S, Parravano M, Bailey C, Chaudhary V, Albrecht T, Ishida S, Uschner D, Lövestam-Adrian M, Luna Pinto J, Schweitzer J, Sheth V, Souied E, Guymer R
Duration 60mins Vienna, Austria
Impact of the Port Delivery Platform With Ranibizumab (PDS) on Service Capacity in High Treatment Burden Patients with nAMD
Johannes Keller, Somnath Banerjee, Lucia Munoz Bohollo, Vana Papaleonida, Shakti Kasbia, Rachel Le Sueur
Duration 60mins Vienna, Austria
Pagoda Trial Results Through Year 4: Port Delivery Platform With Ranibizumab for the Treatment of Diabetic Macular Edema
Jordan Graff
Duration 60mins Vienna, Austria
Low Risk of Proliferative Vision-Threatening Complications Observed in Patients with Diabetic Eye Disease Treated with Continuous Delivery via the Port Delivery Platform with Ranibizumab (PDS)
Sobha Sivaprasad, Manjot K. Gill, Carl C. Awh, Chandrakumar Balaratnasingam, Aude Couturier, Andres Emanuelli, Ivan J. Suñer, Vivian Chen, Paul Latkany, Albert Plenty, Shamika Gune
Duration 60mins Vienna, Austria
Early Insights From Real-World Use of the Port Delivery Platform With Ranibizumab (PDS) Among Eyes With nAMD Switching From Intravitreal Anti-VEGF Injections
Adam Pflugrath, Josee Winsor, Anastasios Dakouras, Andrew Gordon, Jiying Zou, Ronald A Cantrell
10:48 AM
Duration 6mins Vienna, Austria
Early Real-World Effectiveness and Safety of Faricimab▼ in Eyes With Retinal Vein Occlusion: 6-Month Results From the UK FARWIDE-RVO Study
Christine Kiire, Gale R, Sivaprasad S, Pearce I, Talks J, Downey L, Varma D, Chi G, Darnell A, Dodds M, Dayal P
01:12 PM
Duration 6mins Vienna, Austria
One-year Clinical and Anatomical Outcomes of Faricimab▼ Treatment in Eyes With nAMD From the Global, Prospective Observational VOYAGER Study
Robyn Guymer, Aboobaker S, Sheth V, Schmitz-Valckenberg S, Parravano M, Bailey C, Chaudhary V, Chi G, Ishida S, Uschner D, Koh A, Lövestam-Adrian M, Luna Pinto J, Schweitzer J, Souied E
01:48 PM
Duration 6mins Vienna, Austria
Up to 7-Year Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery Platform With Ranibizumab (PDS): Results From the Portal Extension Trial
Mahi Muqit, Caesar Luo, Jordan M. Graff, John Kitchens, Gian-Andrea Thanei, Steven Blotner, Shamika Gune, Dolores Berger Lassalle, Mel Rabena, Natasha Singh, Insaf Saffar
06:42 AM
Duration 6mins Vienna, Austria
Evaluation of the Role of Interleukin-6 and Vascular Endothelial Growth Factor in Uveitic Macular Edema and Uveitis
Niamh Gould, Edmund Tsui, Marina Mesquida, Nisha Acharya, Daniela Willen, William Holmes, Andreas Dieckmann, Meike Pauly-Evers, Laura Steeples, Zdenka Haskova, Sascha Fauser, Zeinab Barekati
06:48 AM
Duration 6mins Vienna, Austria
Intraocular Dynamics of IL-6 Signaling Pathways in Uveitic Macular Edema: Evidence From the Phase 1 DOVETAIL Trial
Zeinab Barekati, Eric Suhler, Phoebe Lin, Federica Storti, Rachael Harlow, Gregor Jordan, Guido Steiner, Anna Rautanen, Benedicte Passemard, Laura Steeples, Sascha Fauser, Marina Mesquida
10:24 AM
Duration 6mins Vienna, Austria
Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Patients With Retinal Vein Occlusion from a Global, Prospective Observational Study: The VOYAGER Study
Prof Hattenbach, Lövestam-Adrian M, Chaudhary V, Schmitz-Valckenberg S, Parravano M, Bailey C, Chaikitmongkol V, Finger R, Ishida S, Uschner D, Koh A, Schweitzer J, Souied E, Sheth V, Guymer R
10:48 AM
Duration 6mins Vienna, Austria
Better Visual Outcomes With Faricimab▼ vs Aflibercept 2 mg in Patients With Treatment-Naïve nAMD Who Had Small Lesions: A TENAYA/LUCERNE Post Hoc Analysis
Enrico Borrelli, Eric Nudleman, Nicholas Dagincourt, Florie Mar, Shriji Patel, Philippe Margaron
10:54 AM
Duration 6mins Vienna, Austria
Port Delivery Platform With Ranibizumab Treatment in Eyes With Neovascular Age-Related Macular Degeneration and High Injection Burden
Margaret Chang, Michael A. Klufas, Jeffrey K. Moore, Eric P. Suan, Robert S. Wirthlin, Steven Blotner, Brianne Chin, Andrew Gordon, Shamika Gune
09:30 AM
Duration 6mins Vienna, Austria
Long-Term Effectiveness and Safety of Faricimab▼ in Eyes With Diabetic Macular Edema: 2-Year Results From the UK FARWIDE Study
Tunde Peto, Sivaprasad S, Kiire C, Reynolds R, Bailey C, Downey L, Pearce I, Chi G, Darnell A, Dodds M, Dayal P
09:36 AM
Duration 6mins Vienna, Austria
The Molecular Pathophysiology of Uveitic Macular Edema: An Exploratory Analysis From the DOVETAIL Vamikibart Phase 1 Study
Zeinab Barekati, Juliane Siebourg-Polster, Federica Storti, Andreas Dieckmann, Meike Pauly-Evers, William Holmes, Gregor Jordan, Denise Sickert, Benedicte Passemard, Laura Steeples, David Silverman, Sascha Fauser, Marina Mesquida
12:33 PM
Duration 6mins Vienna, Austria
Quantitative Analysis of Foveal Avascular Zone Following Faricimab▼ in Treatment-Naïve DME: An ALTIMETER OCT-A Post Hoc Analysis
Aude Couturier, Le Boité H, Gallardo M, Eap M, Gibson K, Yang M, Patel S, Titz B, Benech A, Vazquez-Lombardi C
01:03 PM
Duration 6mins Vienna, Austria
Assessment of Intraretinal Cyst Turbidity on Optical Coherence Tomography: Clinical Implications in Eyes With DME From the YOSEMITE/RHINE Trials
Vas Sadda, Andreas Pollreisz, Jenny Lim, Isabel Bachmeier, Yaniv Cohen, Ali Boushehri, Manuel Amador, Alexandra Warter, Nicholas Dagincourt, Kara Gibson
01:36 PM
Duration 6mins Vienna, Austria
Faricimab▼ for Polypoidal Choroidal Vasculopathy: 2-Year Results From the Phase 3b/4 SALWEEN Trial
Timothy Lai, Gemmy Cheung, Shih-Jen Chen, Shigeru Honda, Adrian Hock Chaun Koh, Min Sagong, Won Ki Lee, Xiaorong Li, Paisan Ruamviboonsuk, Xiaodong Sun, Yasuuo Yanagi, Ruobing Bai, Xiaoying Yang, Philippe Margaron
01:42 PM
Duration 6mins Vienna, Austria
Long-Term Effectiveness and Safety of Faricimab▼ in Eyes With Neovascular Age-Related Macular Degeneration: 2-Year Results From the UK FARWIDE Study
Gabriella de Salvo, Pearce I, Varma D, Talks J, Patel P, De Silva S, Gale R, Chi G, Darnell A, Dodds M, Dayal P
07:42 AM
Duration 7mins Vienna, Austria
Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: Pooled Results from the Phase 3 MEERKAT and SANDCAT Trials
Carlos Pavesio, Lyndell Lim, Eric Suhler, Rahul N. Khurana, Koh-Hei Sonoda, Mark Lomax, Deanna Galloway, Emma Harrell, Marina Mesquida, Zdenka Haskova, David Silverman, Ivo Stoilov, André Vicente, Laura Steeples, Nisha Acharya
12:15 PM
Duration 6mins Vienna, Austria
Impact of Novel Anti-Hyperglycemic Drugs on Visual Outcomes in Anti-VEGF Treated Diabetic Macular Edema Patients: A Real World Data Analysis
Aleksandra Rachitskaya, Parul Dayal, Niamh Gould, Shu Wang, Kayo Kimura, Nisha B. Shah, Zeinab Barekati, Diane Uschner, Pablo Arrisi, Shriji Patel, Dawn A. Sim
Coming soon